I don't think you interpreted the CC comments on FMD Vaccine correctly. I believe it was clear the Vaccine was not Approved for general use in the U.S., nor would it be by November when Homeland Security intends to add to the Strategic Reserve. I believe it's clear that GNVC's vaccine is what's being added to the Strategic Reserve, and that H.S. may add a vaccine that's not yet fully approved in the same way that the D.O.D. may use drugs that aren't FDA Approved.
As for a Partnership, in that GNVC doesn't have the manufacturing capability, when H.S. acts to add to the Strategic Reserve, someone will need to have the rights to do so, they will either be a partner of GNVC or have some sort of license from them, and yes, GNVC will be paid.
It would be desirable for a major partnership, i.e. someone with the rights to pursue gaining approval for the vaccines worldwide, and full manufacturing, distribution and sales rights. Certainly a partner who acquires all these rights from GNVC will pay GNVC far more than someone who's only licensed to provide vaccines to H.S. for this one order. Those are the extremes, we could get something in the middle, perhaps someone with U.S. rights, leaving the rest of the world still available.
What's important is however it comes down, GNVC will be paid, and the payment should be substantial enough to see GNVC through to TNFerade approval, at least if it comes by 2011.
It's just over 2 months till November, that's not too long to wait. While I believe the partnership could come at any time, it's also possible that a license has already been agreed on as part of GNVC's original agreement with H.S. I.E. when H.S. contracts with a manufacturer for the vaccine, GNVC would be paid according to something that's already established in the H.S. agreement. It would be up to GNVC and the manufacturer to determine if they wanted to take that agreement any further.
Gary
News 
Market Data 
Discover 
